This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Upon completion of the program, participants should be able to:

• Describe and address risk factors that contribute to the continued spread of HIV, especially in high-risk and underserved populations
• Review the need for strategies to reduce the risk of new infections with HIV in various populations
• Explain the rationale behind various behavioral and medical interventions designed to improve linkage to HIV care and improve treatment outcomes
• Identify and address barriers to optimal HIV treatment in various populations, including STI, PWID, and underserved populations

Back to Top

Physician Continuing Education:

PACE designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Develpment:

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Pharmacy Continuing Education:

PACE designates this continuing medical education activity for 2.0 contact hour(s)(0.2 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008073-9999-24-135-H02-P

Type of Activity: Application

For Pharmacists: Upon successfully completing the activity evalutation, your credit will be submitted to CPE Monitor.  Please check your NABP account within (30) days to make sure the credit has posted.

PA Continuing Medical Education:

PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until July 2, 2025. PAs should only claim credit commensurate with the extent of their participation.

Back to Top

Disclosure of Conflicts of Interest:

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling or distributing healthcare products by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no financial relationships.

The PIM planners and others have nothing to disclose.

Back to Top

Instructions for Credit

1. There are no fees for participating in and receiving CME credit for this activity.
2. During the period July 2, 2024, through July 2, 2025, participants must read the educational objectives and faculty disclosures and study the educational activity.
3. If you wish to receive acknowledgment for completing this activity, please complete the activity evaluation, using the link below.
4. Upon registering and successfully completing activity evaluation, your certificate will be made available immediately.

To Claim Credit for this program, please go to: https://paceducation.com/HIVTxPrevention2024

For additional information about the accreditation of this activity, please visit: https://partnersed.com

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Computer System Requirements

This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.